Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual MeetingBusiness Wire • 04/12/23
Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Company's Multi-Omics Capabilities and Tools for Biopharma PartnersBusiness Wire • 03/15/23
Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley BankBusiness Wire • 03/11/23
Double-Digit Sales Growth: Is This Stock a Convincing Buy for Growth Investors?The Motley Fool • 03/10/23
Data Published in “The Red Journal” Validate Prognostic Value of Veracyte's Decipher Prostate Genomic Classifier for Men with High-Risk Prostate CancerBusiness Wire • 02/15/23
Veracyte to Release Fourth Quarter and Full-Year 2022 Financial Results on February 22, 2023Business Wire • 02/06/23
Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers SymposiumBusiness Wire • 02/01/23
Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid NodulesBusiness Wire • 02/01/23
Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte's Afirma GSC in Thyroid Cancer DiagnosisBusiness Wire • 12/15/22
Veracyte Announces Three Abstracts to Be Presented at SITC 2022 Annual MeetingBusiness Wire • 11/01/22
Veracyte to Participate in the Credit Suisse 31st Annual Healthcare ConferenceBusiness Wire • 10/27/22
New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose RadiotherapyBusiness Wire • 10/25/22
Veracyte Data Presented at ATA Annual Meeting Provide New Insights into Molecular Underpinnings of Thyroid CancerBusiness Wire • 10/24/22